In this phase 2 trial, YKYY017, a SARS-CoV-2 membrane fusion inhibitor, was tested against mild to moderate COVID-19. Inhaled YKYY017 at 20 mg produced a numerically higher viral load reduction compared with placebo on Day 4, suggesting potential antiviral activity. Both inhaled 10 mg and 20 mg YKYY017 were well-tolerated and had acceptable safety profiles.
- Yeming Wang
- Lianhan Shang
- Bin Cao
